Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
BMC Endocr Disord ; 22(1): 320, 2022 Dec 19.
Artigo em Inglês | MEDLINE | ID: mdl-36529727

RESUMO

INTRODUCTION: Regarding the increased prevalence of obesity among children and adolescents, and the impact of obesity on insulin resistance (IR) and other metabolic disorders, this study was performed to determine the association of cardiometabolic risk factors (CMRFs) with IR in overweight and obese children. METHOD: In this cross-sectional study 150 overweight and obese children (BMI ≥ 85th and BMI ≥ 95th age-sex specific percentile) and adolescents were selected via convenient sampling method from Endocrinology clinic in Karaj; Iran in 2020. Anthropometric indices, lipid profile, fasting blood glucose (FBG), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) were evaluated. IR was defined as HOMA-IR ≥ 2.6. Multivariable linear and logistic regression model was used to assess the association of CMRFs with insulin level and IR respectively. RESULTS: The mean age of children was 10.37 (± 2.6) years. Fifty-four percent of the participants were girls. IR was increased through increasing age (P < 0.001). In the multivariate logistic regression model, by increasing each unit increment in waist circumference (OR: 1.03, 95% CI: 1.01-1.06), wrist circumference (OR: 1.47, 95% CI: 1.06-2.02) total cholesterol (OR: 1.01, 95% CI: 1.003-1.03) and FBG (OR: 1.11, 95% CI: 1.05-1.18) the odds of IR increased significantly. Moreover, in the adjusted linear regression model, HOMA-IR was associated significantly with waist to height ratio (ß: 2.45), and FBG (ß: 0.02). CONCLUSION: There was a significant association between some CMRFS with IR in overweight and obese children.


Assuntos
Resistência à Insulina , Obesidade Infantil , Adolescente , Masculino , Feminino , Criança , Humanos , Sobrepeso/epidemiologia , Fatores de Risco Cardiometabólico , Estudos Transversais , Obesidade Infantil/complicações , Obesidade Infantil/epidemiologia , Índice de Massa Corporal , Fatores de Risco , Glicemia/metabolismo , Insulina
2.
Diabetes Metab Syndr ; 16(5): 102499, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35580523

RESUMO

BACKGROUND AND AIMS: The COVID-19 pandemic has prompted researchers to look for effective therapeutic targets. The effect of endocannabinoid system against infectious diseases is investigated for several years. In this study, we evaluated the expression level of CNR1 and CNR2 genes in patients with COVID-19 with and without diabetes to provide new insights regarding these receptors and their potential effect in COVID-19 disease. METHODS: In this study, peripheral blood monocytes cells (PBMCs) were isolated from eight different groups including COVID-19 patients, diabetic patients, and healthy individuals. RNA were extracted to evaluate the expression level of CNR1 and CNR2 genes using real-time PCR. The correlation between the expression levels of these genes in different groups were assessed. RESULTS: A total of 80 samples were divided into 8 groups, with each group consisting of ten samples. When comparing severe and moderate COVID-19 groups to healthy control group, the expression levels of the CNR1 and CNR2 genes were significantly higher in the severe and moderate COVID-19 groups. There were no significant differences between the mild COVID-19 group and the healthy control group. It was found that the expression levels of these genes in patients with diabetes who were infected with SARS-COV-2 did not differ across COVID-19 groups with varying severity, but they were significantly higher when compared to healthy controls. CONCLUSION: Our study suggests the possible role of endocannabinoid system during SARS-COV-2 pathogenicity as the expression of CNR1 and CNR2 were elevated during the disease.


Assuntos
COVID-19 , Diabetes Mellitus , Receptor CB1 de Canabinoide , Receptor CB2 de Canabinoide , COVID-19/sangue , COVID-19/genética , COVID-19/metabolismo , COVID-19/virologia , Diabetes Mellitus/sangue , Diabetes Mellitus/genética , Diabetes Mellitus/metabolismo , Diabetes Mellitus/virologia , Endocanabinoides/farmacologia , Expressão Gênica , Humanos , Pandemias , Receptor CB1 de Canabinoide/biossíntese , Receptor CB1 de Canabinoide/genética , Receptor CB2 de Canabinoide/biossíntese , Receptor CB2 de Canabinoide/genética , SARS-CoV-2
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA